Vivani Medical Statistics
Total Valuation
Vivani Medical has a market cap or net worth of $94.71 million. The enterprise value is $97.53 million.
Important Dates
The last earnings date was Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vivani Medical has 90.20 million shares outstanding. The number of shares has increased by 40.02% in one year.
| Current Share Class | 90.20M |
| Shares Outstanding | 90.20M |
| Shares Change (YoY) | +40.02% |
| Shares Change (QoQ) | +3.48% |
| Owned by Insiders (%) | 49.96% |
| Owned by Institutions (%) | 6.42% |
| Float | 38.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.17 |
| P/TBV Ratio | 7.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 1.32.
| Current Ratio | 2.40 |
| Quick Ratio | 2.26 |
| Debt / Equity | 1.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -372.18% and return on invested capital (ROIC) is -70.08%.
| Return on Equity (ROE) | -372.18% |
| Return on Assets (ROA) | -58.33% |
| Return on Invested Capital (ROIC) | -70.08% |
| Return on Capital Employed (ROCE) | -98.04% |
| Weighted Average Cost of Capital (WACC) | 19.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$643,643 |
| Employee Count | 42 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.57% in the last 52 weeks. The beta is 3.32, so Vivani Medical's price volatility has been higher than the market average.
| Beta (5Y) | 3.32 |
| 52-Week Price Change | -28.57% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 42.95 |
| Average Volume (20 Days) | 285,272 |
Short Selling Information
The latest short interest is 369,789, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 369,789 |
| Short Previous Month | 417,148 |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.95% |
| Short Ratio (days to cover) | 2.24 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.16M |
| Pretax Income | -27.03M |
| Net Income | -27.03M |
| EBITDA | -27.66M |
| EBIT | -28.16M |
| Earnings Per Share (EPS) | -$0.33 |
Full Income Statement Balance Sheet
The company has $14.59 million in cash and $17.41 million in debt, with a net cash position of -$2.82 million or -$0.03 per share.
| Cash & Cash Equivalents | 14.59M |
| Total Debt | 17.41M |
| Net Cash | -2.82M |
| Net Cash Per Share | -$0.03 |
| Equity (Book Value) | 13.22M |
| Book Value Per Share | 0.15 |
| Working Capital | 9.25M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$25.34 million and capital expenditures -$376,000, giving a free cash flow of -$25.72 million.
| Operating Cash Flow | -25.34M |
| Capital Expenditures | -376,000 |
| Depreciation & Amortization | 502,000 |
| Net Borrowing | -356,000 |
| Free Cash Flow | -25.72M |
| FCF Per Share | -$0.29 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vivani Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -40.02% |
| Shareholder Yield | -40.02% |
| Earnings Yield | -31.29% |
| FCF Yield | -27.15% |
Analyst Forecast
The average price target for Vivani Medical is $3.83, which is 265.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.83 |
| Price Target Difference | 265.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |